Dendritic-cell-derived osteoclasts: a new game changer in bone-resorption-associated diseases - Archive ouverte HAL Access content directly
Journal Articles Drug Discovery Today Year : 2016

Dendritic-cell-derived osteoclasts: a new game changer in bone-resorption-associated diseases

(1, 2) , (3) , (1, 2, 4) , (1, 2) , (1, 2, 4)
1
2
3
4

Abstract

Dendritic cells are major contributors to inflammatory bone destruction in human through RANKL mediation and could represent a new therapeutic target. Bone-resorbing cells, osteoclasts (OCs), and antigen-presenting cells, dendritic cells (DCs), share several features. They are derived from a common hematopoietic precursor, exhibit phagocytic activities and their functions are dependent upon receptor activator of nuclear factor kB ligand (RANKL). Upon inflammatory conditions, DCs can transdifferentiate toward functional OCs in the presence of RANKL. It has then been assumed that the increase in proinflammatory cytokines could provide a supportive environment for this transdifferentiation. In this review, we emphasize the molecular mechanisms underlying the potential for DCs to give rise to resorbing OCs in the context of bone-destruction-associated diseases upon inflammatory conditions. Whether these mechanisms reveal new strategies for the discovery of therapeutic targets and drugs is discussed extensively.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-01845424 , version 1 (20-07-2018)

Identifiers

Cite

Olivier Lapérine, Claudine Blin-Wakkach, Jérôme Guicheux, Sarah Beck-Cormier, Philippe Lesclous. Dendritic-cell-derived osteoclasts: a new game changer in bone-resorption-associated diseases. Drug Discovery Today, 2016, 21 (9), pp.1345 - 1354. ⟨10.1016/j.drudis.2016.04.022⟩. ⟨inserm-01845424⟩
56 View
1 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More